Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter In 20-Year Supply Pact | Contract Pharma
Breaking News

Baxter In 20-Year Supply Pact

To provide recombinant factor VIII (rFVIII) in Brazil

Baxter International Inc. has entered an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A.

“Our unique collaboration with Hemobrás is a demonstration of Baxter’s leadership in hemophilia, reflects our expertise and commitment to the community, and positions us as an attractive partner that can make a significant impact on expanding access to quality care to patients around the world,” said Robert L. Parkinson, Jr., Baxter chairman and chief executive officer. “This agreement establishes Baxter as the provider of choice in Brazil and builds upon Baxter’s long-standing presence in this large and growing market.”

Baxter will be the exclusive provider of Brazil’s recombinant FVIII treatment for the next 10 years while the companies work on the technology transfer to support development of local manufacturing capacity by Hemobrás. Baxter will receive cash payments for product supplies and following completion of the technology transfer, royalties on recombinant FVIII produced by Hemobrás. The company expects annual sales to exceed $200 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters